Fulcrum Therapeutics (NASDAQ:FULC – Get Rating) had its target price lowered by investment analysts at SVB Securities from $18.00 to $10.00 in a report issued on Friday, The Fly reports. SVB Securities’ price target points to a potential upside of 121.73% from the company’s current price.
FULC has been the subject of a number of other research reports. Piper Sandler boosted their target price on Fulcrum Therapeutics from $18.00 to $21.00 and gave the stock an “overweight” rating in a report on Monday, January 23rd. Morgan Stanley cut Fulcrum Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $27.00 to $8.00 in a report on Monday, February 27th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating in a report on Friday, February 24th. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $35.00 to $6.00 in a report on Thursday. Finally, The Goldman Sachs Group upped their price target on Fulcrum Therapeutics from $11.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, January 19th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $12.00.
Fulcrum Therapeutics Stock Performance
Shares of NASDAQ:FULC opened at $4.51 on Friday. Fulcrum Therapeutics has a 1 year low of $3.21 and a 1 year high of $24.79. The stock has a market capitalization of $234.75 million, a P/E ratio of -1.82 and a beta of 2.25. The stock has a 50-day simple moving average of $10.75 and a 200-day simple moving average of $8.31.
Insider Buying and Selling at Fulcrum Therapeutics
Institutional Investors Weigh In On Fulcrum Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in FULC. RA Capital Management L.P. acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter valued at approximately $56,630,000. Point72 Asset Management L.P. raised its position in shares of Fulcrum Therapeutics by 511.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,988,800 shares of the company’s stock valued at $9,745,000 after acquiring an additional 1,663,800 shares in the last quarter. VR Adviser LLC bought a new position in Fulcrum Therapeutics during the 3rd quarter worth $9,708,000. Sofinnova Investments Inc. bought a new position in Fulcrum Therapeutics during the 3rd quarter worth $6,450,000. Finally, Nantahala Capital Management LLC bought a new position in Fulcrum Therapeutics during the 4th quarter worth $3,640,000.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T.
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.